Collegium Pharmaceutical (COLL) Cash from Investing Activities (2015 - 2026)

Collegium Pharmaceutical's Cash from Investing Activities history runs 12 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 116.81% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was -$52.2 million, a 81.3% increase from a year earlier, with the FY2025 full-year figure at -$63.5 million, up 77.92% from the prior year.
• Cash from Investing Activities improved to $1.6 million in Q1 2026 per COLL's latest filing, from -$20.1 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $1.6 million in Q1 2026 and bottomed at -$572.2 million in Q1 2022.
• The 5-year median for Cash from Investing Activities is -$9.7 million (2025), against an average of -$58.5 million.
• Across the five-year window, Cash from Investing Activities tumbled 133586.21% in 2022 and jumped 116.81% in 2026, its largest moves.
• Year by year, Cash from Investing Activities stood at -$940000.0 in 2022, then plunged by 2569.89% to -$25.1 million in 2023, then surged by 53.13% to -$11.8 million in 2024, then tumbled by 70.63% to -$20.1 million in 2025, then jumped by 108.11% to $1.6 million in 2026.
• Per Business Quant, the three latest COLL Cash from Investing Activities figures stand at $1.6 million (Q1 2026), -$20.1 million (Q4 2025), and -$30.9 million (Q3 2025).